Company Updates
Petrology Confirms Porphyr Copper-Gold at Crater Mountain
Gold Anomaly (ASX: GOA) has received a final report on the petrology and mineralogy of drill core from hole NEV033 at the Nevera Prospect at the flagship Crater Mountain project, Papua New Guinea (PNG). The report by Mr Anthony Coote of Applied Petrologic Services & Research in New Zealand (“APSAR”), includes a detailed discussion of his findings which confirm […]
PrIME Completes First Three Trial Production Runs of Albumin in Singapore GMP Facility
Sydney, Australia 8th January 2013-NuSep (ASX:NSP) wishes to advise the market that staff at its Singapore subsidiary PrIME Biologics has successfully completed three trial production runs of Human Albumin using its pilot production unit in Singapore current Good Manufacturing Practice (cGMP) production facility. These trial production runs were completed in a cGMP environment using human […]
NuSep Receives Final Tranche Payment Under 15% Share Placement
Sydney, Australia 2nd January 2013- The Board of NuSep (ASX:NSP) wishes to advise the market that it has received the third and final payment of $227,090.75 as per the terms of the 15% share placement announced to the market on 30 October 2012. Of the $1, 167, 090.75 placement previously announced, $940, 000 was receive […]
Update on Sale of Swedish Copper Prospect
Hannans Reward Ltd (Hannans)(ASX:HNR) and Avalon Minerals Limited (Avalon) (ASX:AVI) announced on 16 October 2012 that they had signed a binding Heads of Agreement (HoA) in relation to the sale and purchase of the Discovery Zone Prospect, located in Kiruna, Sweden. On 26 November 2012 the companies agreed to extend the Due Diligence period through to 21 December […]
Ironwood Begins Phase I Trial of Investigation IW-2143 Anxiety Drug in US
Bionomics Limited (ASX: BNO) (ADR: BMICY) has been advised by its licensee Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) that, following the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) last month, the planned Phase I clinical trial of the investigational anti-anxiety drug candidate IW-2143 (BNC210) has begun in the […]
IW-2143 Anxiety Drug in US
Bionomics Limited (ASX: BNO) (ADR: BMICY) has been advised by its licensee Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) that, following the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) last month, the planned Phase I clinical trial of the investigational anti-anxiety drug candidate IW-2143 (BNC210) has begun in the […]
Folkestone Completes Unlisted Fund Capital Raising
The Fund is a single asset, closed end, unlisted real estate fund which owns 7 Murray Rose Ave, Sydney Olympic Park (Asset), a recently completed 5,920 square metre commercial office building comprising five levels of office space and ground floor retail, and two levels of basement carparking. Thales, Australia, part of Thales Group, a leading […]
Results of Liver Fibrosis Project
Resonance Health has been undertaking a project with the aim to develop an MRI based technology to detect and measure liver fibrosis. The Company has conducted a number of studies which have shown some promising results. In 2011/12, the Company undertook an additional study in collaboration with the Austin Health liver unit in Victoria to […]
Company Update – Marianas project
Condor Blanco Mines Limited (“Condor Mines”, “the Company”) has advanced negotiations in regards to off-take agreements at its Marianas iron tailings project in Copiapo, Chile. It anticipates a resulting Heads of Agreement will be signed early in the new year. The discussions follow on from Memorandums of Understanding Condor Mines signed in September with Changes Investment Guarantee (China) […]
Backed By Leading Investment Groups and Family Offices
